InNexus Biotechnology, Inc.
IXSBFOTCHealthcare
$0.00
+$0.00(+0.00%)
Market Cap$12627
P/E Ratio—
52W High$0.0001
52W Low$0.000001
InNexus Biotechnology, Inc. (IXSBF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · IXSBF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2010-06 | 2009-06 | 2008-06 | 2007-06 | 2006-06 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.00B | $0.00B | ($0.00B) | ($0.00B) | ($0.00B) |
| Gross Margin %(computed) | — | — | — | — | -347.90% |
| Operating Expenses | |||||
| R&D Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| G&A Expenses | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Total Operating Expenses | $0.00B | $0.01B | $0.01B | $0.01B | $0.00B |
| Operating Income | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| Operating Margin %(computed) | — | — | — | — | — |
| Interest Income | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.01B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| Net Margin %(computed) | — | — | — | — | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-0.07 | $-0.11 | $-0.11 | $-0.13 | $-0.12 |
| Wtd Avg Shares | 0.10B | 0.08B | 0.06B | 0.04B | 0.03B |
| EBITDA | ($0.00B) | ($0.01B) | ($0.01B) | ($0.01B) | ($0.00B) |
| EBITDA Margin %(computed) | — | — | — | — | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · CAD · B
Explore more InNexus Biotechnology, Inc. data
About InNexus Biotechnology, Inc. (IXSBF) Income Statement
InNexus Biotechnology, Inc. (IXSBF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2010, IXSBF reported revenue of $0.00B, gross profit of $0.00B (gross margin —), and net income of ($0.01B) — a net profit margin of —.
Frequently asked questions
IXSBF · 4 questionsInNexus Biotechnology, Inc. (IXSBF) reported revenue of $0.00B for 2010, down —% year-over-year.
IXSBF revenueIXSBF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09